關于我們
ABOUT US
公司簡介
宜昌博仁凱潤藥業有限公司成立于2019年8月，主要批量生產國際熱銷的的PEG linkER類鏈接劑產品,同時還開發和生產PEG linkER修飾過的納米脂質體配方材料、親脂類納米顆粒配方材料，為國內外急需的藥物定向輸送行業提供可靠材料和技術支持。現有的藥物定向傳輸技術多以開發新的生物靶向分子來導引現有的藥物，宜昌博仁凱潤藥業有限公司開發的藥物傳輸中間體是利用現有的納米顆粒導向技術，實現已有靶向分子和現有的治療制劑的快速結合（利用我們的聚乙二醇鏈接劑技術），從而可以快速開發出成千上萬種靶向分子制導的治療制劑的藥物庫，然后與臨床治療結合，可以篩選出最適合治療病人的醫療制劑，從而實現對病人的最佳個性化治療。
Founded in August 2019, Yichang Boren Kelun Pharmaceutical Co., Ltd. is mainly engaged in mass production of PEG linkER linkER linker products, and also develops and produces PEG linkER modified nano-liposome formula materials and lipophilic nanoparticle formula materials. To provide reliable materials and technical support for the urgently needed drug delivery industry at home and abroad. The existing targeted drug delivery technology is mainly to develop new biological targeted molecules to guide existing drugs. The drug delivery intermediate developed by Yichang Boren Kelun Pharmaceutical Co., Ltd. utilizes the existing nanoparticle guidance technology to realize the rapid combination of existing targeted molecules and existing therapeutic agents (using our polyethylene glycol linker technology). Thus, a drug library of thousands of targeted molecular guided therapeutic agents can be rapidly developed, and then combined with clinical treatment, the most suitable medical agents can be selected to treat patients, so as to achieve the best personalized treatment for patients.
